The Trump administration’s impact on gene therapy has been a topic of interest for researchers, advocates, and industry executives. This was highlighted during a recent “Cell and Gene Therapy Roundtable” convened by the Food and Drug Administration (FDA).
The event was described as unusual, with many panelists admitting they were unsure of the meeting’s agenda or purpose. Despite the lack of specifics, guests from various sectors, including academia, advocacy, and industry, were asked to provide brief statements on what the FDA should know about cell and gene therapy. This portion of the meeting lasted two hours.
Health Secretary Robert F. Kennedy Jr., National Institutes of Health Director Jay Bhattacharya, and Centers for Medicare and Medicaid Services Administrator Mehmet Oz then shared their statements. However, their presentations left little time for further discussion, with only 10 minutes remaining by the end of the session.
The exclusive details of the meeting were available to STAT+ subscribers, who could access additional coverage and analysis of the biotech sector by subscribing to the platform. For those interested in reading the full article, a subscription to STAT+ was required.
Overall, the Cell and Gene Therapy Roundtable provided a glimpse into the potential implications of the Trump administration on gene therapy. With key stakeholders sharing their insights and perspectives, it remains to be seen how this field will evolve under the current administration.
